Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03193463
Recruitment Status : Withdrawn (PI left institution)
First Posted : June 20, 2017
Last Update Posted : March 1, 2019
Sponsor:
Collaborator:
Infuseon Therapeutics, Inc.
Information provided by (Responsible Party):
Michael Vogelbaum, MD, PhD, Case Comprehensive Cancer Center

Brief Summary:

The purpose of this study is to determine if treatment with topotecan by an alternative method, direct delivery into brain tumors, is safe and well tolerated. The Cleveland Multiport Catheter is a new, investigational device that will be used to deliver topotecan into your brain tumor. A second purpose of this study is to determine whether the Cleveland Multiport Catheter can be used effectively and safely to deliver topotecan into your brain tumor.

This study will also determine the best dose of topotecan to deliver to your tumor with use of the Cleveland Multiport Catheter and will also examine how your tumor responds to treatment with topotecan.


Condition or disease Intervention/treatment Phase
Glioma Drug: Topotecan (<=8cc) Drug: Topotecan (>8cc) Device: Cleveland Multiport Catheter Diagnostic Test: Magnetic Resonance Imaging (MRI) Drug: Lower Does Topotecan Early Phase 1

Detailed Description:

Primary Objectives

  • To investigate by MR imaging the spatial and temporal distribution of topotecan in enhancing or nonenhancing bulk tumor administered by convection-enhanced delivery (CED) in patients with recurrent/progressive WHO grade III or IV (high grade) glioma (HGG) who have failed standard therapy comprising surgical biopsy and/or resection and adjuvant chemotherapy and radiotherapy.
  • To investigate by MR imaging the influence of the rate and topotecan concentration, on the spatial and temporal distribution of topotecan administered by CED in patients with with recurrent/progressive HGG

Secondary Objectives

  • To investigate the extent to which backflow may be observed on MRI during CEDmediated delivery of topotecan
  • To assess the safety, tolerability and toxicity profile of topotecan administered by CED using different doses and infusion rates.
  • To observe evidence of activity of single-agent topotecan administered by CED to patients with recurrent/progressive HGG who have failed standard therapy comprising surgical biopsy and/or resection and adjuvant chemotherapy and radiotherapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

There will be 3 arms to this study, and they will accrue independently of each other as they reflect distinctly separable populations of patients with rHGG.

Arm 1: Predominantly enhancing mass with volume of 8 cc or less. Arm 2: Predominantly enhancing mass with volume of > 8 cc Arm 3: Predominantly non-enhancing mass

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Trial of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy (IND 117,240)
Actual Study Start Date : November 3, 2017
Actual Primary Completion Date : November 19, 2018
Actual Study Completion Date : November 19, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy

Arm Intervention/treatment
Experimental: Predominantly enhancing mass with volume of 8 cc or less
Only 1 Cleveland Multiport Catheter (CMC) will be placed and CED will be performed intra-operatively only in a magnetic resonance imaging (MRI) equipped Operating Room. Topotecan infusion will be performed over a 4-hour period, with the goal of complete tumor coverage. The initial rate will be 1.20 ml/hour and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 1.20 ml/hour based upon the tumor coverage and safety characteristics of the previously treated patients.
Drug: Topotecan (<=8cc)
In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
Other Name: Hycamtin

Device: Cleveland Multiport Catheter
an investigational device, will be used to deliver the topotecan

Diagnostic Test: Magnetic Resonance Imaging (MRI)
to monitor the infusion of topotecan into the tumor

Experimental: Predominantly enhancing mass with volume of > 8 cc
2 Cleveland Multiport Catheter (CMCs) will be placed and the total infusion rate of Topotecan per CMC to be used for the first 24 hours for the first patient will be 0.834 ml/hour (3.48 microliters/minute/microcatheter). The rate used for the second 24 hours of the infusion will be 1.668 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.834 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the enhancing tumor by the infused Gadopentetic acid (Gd-DTPA), or 2) rate-limiting toxicity.
Drug: Topotecan (>8cc)
In predominantly enhancing mass with a volume of > 8 cc of topotecan administered. Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
Other Name: Hycamtin

Device: Cleveland Multiport Catheter
an investigational device, will be used to deliver the topotecan

Diagnostic Test: Magnetic Resonance Imaging (MRI)
to monitor the infusion of topotecan into the tumor

Experimental: Predominantly non-enhancing mass
The total infusion rate of Topotecan per Cleveland Multiport Catheter (CMC) to be used for the first 24 hours for the first patient will be 0.29 ml/hour. The rate used for the second 24 hours of the infusion will be 0.58 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.29 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the non-enhancing tumor by the infused Gd-DTPA, or 2) rate-limiting toxicity.
Device: Cleveland Multiport Catheter
an investigational device, will be used to deliver the topotecan

Diagnostic Test: Magnetic Resonance Imaging (MRI)
to monitor the infusion of topotecan into the tumor

Drug: Lower Does Topotecan
Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
Other Name: Hycamtin




Primary Outcome Measures :
  1. Number of intra-operative catheter related complications [ Time Frame: Up to 12 months ]
    Documentation of possible, probable, or definite catheter-related complications

  2. Number of post-operative catheter related complications [ Time Frame: Up to 12 months ]
    Documentation of possible, probable, or definite catheter-related complications

  3. Number of catheter related complications after catheter removal [ Time Frame: Up to 12 months ]
    Documentation of possible, probable, or definite catheter-related complications

  4. Change in the spatial distribution of intratumorally-administered topotecan at serial timepoints using a gadolinium-based contrast agent, as determined by MRI scan [ Time Frame: Up to 12 months ]
  5. Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion rate, as determined by MRI scan [ Time Frame: Up to 12 months ]
  6. Changes in the spatial distribution of intratumorally-administered topotecan at serial timepoints using volumetric magnetic resonance imaging, as determined by MRI scan [ Time Frame: Up to 12 months ]
  7. Changes in the spatial distribution of intratumorally-administered topotecan at serial timepoints using three-dimensional image reconstruction, as determined by MRI scan [ Time Frame: Up to 12 months ]
  8. Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion concentration, as determined by MRI scan [ Time Frame: Up to 12 months ]
  9. Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion duration, as determined by MRI scan [ Time Frame: Up to 12 months ]

Secondary Outcome Measures :
  1. Number of Participants with response as measured by the Response Assessment in Neuro-Oncology (RANO) Criteria [ Time Frame: Up to 12 months ]
    Response includes objective response rate (ORR), median progression-free survival (PFS), proportion progression-free at six months (PFS-6), and median overall survival (OS)

  2. Safety as measured by the common terminology criteria for adverse events (CTCAE) [ Time Frame: Up to 12 months ]
    Safety will be determined through adverse events by arm



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosis of supratentorial WHO Grade III or IV Glioma (High Grade Glioma) that has undergone surgical biopsy or resection followed by adjuvant chemoradiotherapy, that has evidence of recurrence or progression based on imaging studies and a stereotactic biopsy is indicated for confirmation of recurrence/progression
  • Karnofsky Performance Status 70-100
  • MRI demonstration of a stereotactically accessible enhancing mass that does not require resection to relieve clinically significant mass effect
  • Patient understands the procedures and agrees to comply with the study requirements by providing written informed consent
  • Laboratory values within the following ranges:

    • Absolute neutrophil count (ANC) ≥ 1,500 / μL
    • Platelet count ≥ 100,000 / μL
    • Hemoglobin ≥ 10 g / dL
    • prothrombin time (PT) / partial thromboplastin time (PTT) not above institutional norms
    • Estimated glomerular filtration rate (eGFR) of at least 50 mL/min

Exclusion Criteria:

  • Patient is mentally or legally incapacitated at the time of the study
  • Known HIV(+) or has been diagnosed with AIDS
  • Participation in another investigational drug study in the prior 4 weeks
  • Positive pregnancy test in a female
  • Patient, in the opinion of the investigator, is likely to be poorly compliant
  • Diffuse subependymal or cerebrospinal fluid (CSF) disease
  • Tumors involving the cerebellum
  • Tumor enhancement involving both hemispheres
  • Active infection requiring treatment
  • Unexplained febrile illness
  • Radiation or chemotherapy within 4 weeks of enrollment
  • Systemic diseases associated with unacceptable anesthesia or operative risk
  • Inability to undergo magnetic resonance imaging

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03193463


Sponsors and Collaborators
Michael Vogelbaum, MD, PhD
Infuseon Therapeutics, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Michael A. Vogelbaum, MD, PhD Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Layout table for additonal information
Responsible Party: Michael Vogelbaum, MD, PhD, Principal Investigator, Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT03193463     History of Changes
Other Study ID Numbers: INFT1317
First Posted: June 20, 2017    Key Record Dates
Last Update Posted: March 1, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No

Keywords provided by Michael Vogelbaum, MD, PhD, Case Comprehensive Cancer Center:
Topotecan
Convection-Enhanced Delivery

Additional relevant MeSH terms:
Layout table for MeSH terms
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Topotecan
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents